Cargando…
Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting
Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic isozymes expressed in many human tumors and associated with chemoresistance and poor prognosis. They are well-recognized therapy targets and their inhibition was shown to induce tumor volume reduction and chemosensitization in multiple ca...
Autores principales: | Alshaker, Heba, Wang, Qi, Brewer, Daniel, Pchejetski, Dmitri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445839/ https://www.ncbi.nlm.nih.gov/pubmed/30971929 http://dx.doi.org/10.3389/fphar.2019.00303 |
Ejemplares similares
-
Sphingosine Kinase 1 in Breast Cancer—A New Molecular Marker and a Therapy Target
por: Alshaker, Heba, et al.
Publicado: (2020) -
Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors
por: Alshaker, Heba, et al.
Publicado: (2018) -
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016) -
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
por: Alshaker, Heba, et al.
Publicado: (2017) -
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway
por: Alshaker, Heba, et al.
Publicado: (2014)